Fractyl Health, Inc. (NASDAQ:GUTS) Sees Large Growth in Short Interest

Fractyl Health, Inc. (NASDAQ:GUTS - Get Free Report) saw a significant increase in short interest in December. As of December 31st, there was short interest totalling 2,570,000 shares, an increase of 16.3% from the December 15th total of 2,210,000 shares. Currently, 12.5% of the shares of the company are sold short. Based on an average trading volume of 330,200 shares, the short-interest ratio is currently 7.8 days.

Insider Activity

In related news, insider Jay David Caplan sold 64,197 shares of the stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $2.47, for a total transaction of $158,566.59. Following the completion of the transaction, the insider now owns 153,544 shares in the company, valued at approximately $379,253.68. This represents a 29.48 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Harith Rajagopalan sold 96,517 shares of the firm's stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $2.47, for a total transaction of $238,396.99. Following the sale, the chief executive officer now owns 491,329 shares of the company's stock, valued at $1,213,582.63. This trade represents a 16.42 % decrease in their position. The disclosure for this sale can be found here.

Hedge Funds Weigh In On Fractyl Health

A number of institutional investors and hedge funds have recently added to or reduced their stakes in GUTS. Rhumbline Advisers bought a new stake in shares of Fractyl Health in the second quarter valued at approximately $32,000. Massachusetts Financial Services Co. MA raised its holdings in Fractyl Health by 2.7% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 996,383 shares of the company's stock valued at $4,255,000 after acquiring an additional 25,829 shares during the period. Renaissance Technologies LLC purchased a new stake in shares of Fractyl Health during the second quarter worth $61,000. SG Americas Securities LLC purchased a new stake in shares of Fractyl Health during the third quarter worth $33,000. Finally, Beta Wealth Group Inc. bought a new position in shares of Fractyl Health in the third quarter worth $44,000.

Fractyl Health Stock Performance

Fractyl Health stock traded down $0.01 during trading on Friday, hitting $1.80. The stock had a trading volume of 236,286 shares, compared to its average volume of 265,966. The stock's 50 day moving average is $2.11 and its two-hundred day moving average is $2.69. Fractyl Health has a 1 year low of $1.74 and a 1 year high of $14.50. The stock has a market cap of $86.58 million and a price-to-earnings ratio of -0.15. The company has a quick ratio of 5.57, a current ratio of 5.58 and a debt-to-equity ratio of 0.60.

Fractyl Health (NASDAQ:GUTS - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.48) EPS for the quarter, beating analysts' consensus estimates of ($0.50) by $0.02. The firm had revenue of $0.01 million for the quarter. As a group, analysts predict that Fractyl Health will post -1.66 EPS for the current year.

About Fractyl Health

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.